
Please try another search
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.
Name | Age | Since | Title |
---|---|---|---|
Liz Dallimore | - | 2022 | CEO, MD & Director |
Dianne M. Angus | 64 | 2023 | Independent Non-Executive Chairman |
Tim Phillips | - | - | Member of Clinical Advisory Committee |
Terence Budge | 72 | 2021 | Independent Non-Executive Director |
Geoffrey A. Donnan | - | - | Member of Clinical Advisory Committee |
David Blacker | - | - | Chairman of Clinical Advisory Committee |
Paul Bailey | - | - | Member of Clinical Advisory Committee |
Jeffery Saver | - | 2022 | Member of Clinical Advisory Committee |
Mark Etherton | - | 2024 | Independent Non-Executive Director |
Jeannette Joughin | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review